WALTHAM, Mass., Feb. 8, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced three abstracts co-written with Spyre's research partner, Paragon Therapeutics, Inc., highlighting that the Company's co-lead product candidates, SPY001 and SPY002, have been accepted for presentation as posters at the upcoming 19^th Annual Congress of the European Crohn's and Colitis Organisation (ECCO), held February 21-24, 2024, in Stockholm, Sweden. SPY001 is a fully optimized and half-life extended antibody targeting α4β7 and SPY002 is a fully optimized and half-life extended antibody targeting TL1A, both in development for the treatment of IBD.

"We are thrilled to share preclinical findings supporting our two lead programs, SPY001 and SPY002, during the ECCO Congress," said Joshua Friedman, MD, PhD, SVP of Clinical Development of Spyre. "The preclinical potency, selectivity, and drug-like properties of these investigational antibodies match our ideal product profiles. Further, the half-life extension observed in animal studies supports the potential for human dosing every other month or quarterly, which, if supported by clinical trial results, would be a significant improvement compared to today's approved therapies. We are eager to initiate Phase 1 clinical studies in each program this year."

The posters will be available for viewing during the ECCO Congress beginning on Friday, February 23, 2024, and details are as follows:

Title: Development and Characterization of a Novel Extended Half-Life Monoclonal Antibody Drug Candidate Targeting Integrin α4β7 for the Treatment of IBD
Authors: Eric Zhu, Daniel Rios, Rita Vaz, Joshua Friedman, Deanna Nguyen, Andy Spencer, Hussam Shaheen, Jason Oh

Title: A Novel Monoclonal Antibody Drug Candidate SPY001 Targeting Integrin α4β7 for the Treatment of IBD Demonstrates Prolonged Half-Life in Non-Human Primates
Authors: Eric Zhu, Daniel Rios, Rita Vaz, Joshua Friedman, Deanna Nguyen, Andy Spencer, Jason Oh, Hussam Shaheen

Title: Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBD
Authors: Eric Zhu, Daniel Rios, Jacob Milligan, Joana Ministro, Joshua Friedman, Deanna Nguyen, Andy Spencer, Jason Oh, Hussam Shaheen

Full session details can be accessed via the ECCO program.

About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Spyre's management team's expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, Spyre's ability to achieve the expected benefits or opportunities with respect to its pipeline of product candidates such as potential improved dosing regimens of SPY-001 and SPY-002 over approved product candidates, Spyre's preclinical and future clinical development activities, the potential therapeutic benefits and economic value of Spyre's product candidates, and the timing and results of preclinical studies and clinical trials. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "aim," "strategy," "target," "seek," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "predict," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Spyre will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited those uncertainties and factors described under the heading "Risk Factors" and "Note about Forward-Looking Statements" in Spyre's most recent Quarterly Report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Spyre from time to time. Should one or more of these risks or uncertainties materialize, or should any of Spyre's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.

For Investors:   
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com 

© 2024 Canjex Publishing Ltd. All rights reserved.